Skip to main content
. 2022 Mar 11;4(2):e210067. doi: 10.1148/rycan.210067

Figure 3:

(A, B) Axial 68Ga-DOTATATE PET images and (C, D) corresponding PET T1-weighted post-gadolinium-enhancement fusion images from (A, C) the last 10-minute frame at 50–60 minutes after injection and (B, D) the entire 50-minute acquisition period at 10–60 minutes after injection in a 66-year-old woman in group A with a history of World Health Organization grade II meningioma status (same participant as in Fig 1). DOTATATE = tetraazacyclododecane tetraacetic acid octreotate, 68Ga = gallium 68.

(A, B) Axial 68Ga-DOTATATE PET images and (C, D) corresponding PET T1-weighted post-gadolinium-enhancement fusion images from (A, C) the last 10-minute frame at 50–60 minutes after injection and (B, D) the entire 50-minute acquisition period at 10–60 minutes after injection in a 66-year-old woman in group A with a history of World Health Organization grade II meningioma status (same participant as in Fig 1). DOTATATE = tetraazacyclododecane tetraacetic acid octreotate, 68Ga = gallium 68.